Scott Shannon, MD, discusses psychedelic therapies, federal policy shifts, and the barriers slowing mental health innovation.
In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to ...
Meanwhile, ctDNA, a subset of cell-free DNA shed by tumors into the bloodstream, has emerged as a promising non-invasive risk stratification tool. Detection of ctDNA following curative-intent surgery, ...
Anton M. Kolomeyer, MD, PhD, a retina specialist at NJRetina, spoke with The American Journal of Managed Care ® about ...
Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF ...
Young adults with early-onset colorectal cancer (EOCRC), particularly men and non-Hispanic Black and American Indian/Alaskan ...
Santa Clara County Public Health issued a South Bay health alert after 18 Legionella cases were linked to Kaiser Santa Clara, ...
A formal FDA call for repurposing nominations prioritizes areas where unmet need is high and manufacturer incentives to pursue supplemental approvals are limited. Submissions may be grounded in ...
INFERTILITY IS A COMMON CONDITION that affects millions of individuals in the US. According to data from the National Survey of Family Growth, between 2015 and 2019, infertility, in some form, ...
The null finding held up even when researchers sliced the data by geography, income, insurance type, and social vulnerability ...
Private equity (PE) has played a large and growing role in shaping the American health care landscape. Over the past decade ...
Label expansion enables serotype-agnostic use of FcRn blockade in adult gMG, positioning both IV Vyvgart and SC Vyvgart Hytrulo as first approved options regardless of antibody status. ADAPT SERON ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results